Abstract
Atherosclerosis comprises of a chronic disease of the vessels which mainly targets the arterial system. The disease’s main characteristic is the accumulation of inflammatory cells, lipids, smooth muscle cells and connective tissue within the vascular intima layer. The atherosclerotic lesion can be more accurately defined as a fibro-inflammatory lipid plaque. The pathogenesis of the atherosclerotic plaque is a progressive and additive process that usually occurs over decades. Antiplatelet and anticoagulant agents have been the major elements of large trials since decades, in an attempt to promote the primary and secondary prevention of atherothrombosis. The atherosclerotic plaque rupture and the following thrombosis involve, among others, activation of both platelets and coagulation factors, therefore a potential combination of antiplatelet and anticoagulant therapy, particularly in the setting of secondary prevention has been reconsidered in the light of the newly developed oral anticoagulants.
Keywords: Novel oral anticoagulants, peripheral and coronary artery disease.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Novel Oral Anticoagulants in Peripheral Arterial and Coronary Artery Disease
Volume: 12 Issue: 1
Author(s): Angelos Tsipis, Anna-Maria Athanassiadou, Emmanouil Petrou and Ioannis Iakovou
Affiliation:
Keywords: Novel oral anticoagulants, peripheral and coronary artery disease.
Abstract: Atherosclerosis comprises of a chronic disease of the vessels which mainly targets the arterial system. The disease’s main characteristic is the accumulation of inflammatory cells, lipids, smooth muscle cells and connective tissue within the vascular intima layer. The atherosclerotic lesion can be more accurately defined as a fibro-inflammatory lipid plaque. The pathogenesis of the atherosclerotic plaque is a progressive and additive process that usually occurs over decades. Antiplatelet and anticoagulant agents have been the major elements of large trials since decades, in an attempt to promote the primary and secondary prevention of atherothrombosis. The atherosclerotic plaque rupture and the following thrombosis involve, among others, activation of both platelets and coagulation factors, therefore a potential combination of antiplatelet and anticoagulant therapy, particularly in the setting of secondary prevention has been reconsidered in the light of the newly developed oral anticoagulants.
Export Options
About this article
Cite this article as:
Tsipis Angelos, Athanassiadou Anna-Maria, Petrou Emmanouil and Iakovou Ioannis, Novel Oral Anticoagulants in Peripheral Arterial and Coronary Artery Disease, Cardiovascular & Hematological Agents in Medicinal Chemistry 2014; 12 (1) . https://dx.doi.org/10.2174/187152571201141201092628
DOI https://dx.doi.org/10.2174/187152571201141201092628 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neutrophil Cell Count is Related to Hypertension in Workers: A Cross- Sectional Study
Vascular Disease Prevention (Discontinued) Barriers to Risk Stratification Accuracy in Ischemic Heart Disease in Women: The Role of Non-Obstructive Coronary Artery Disease
Current Pharmaceutical Design Vitamin D and Cardiovascular Disease
Current Vascular Pharmacology Positron Emission Tomography: Applications In Drug Discovery and Drug Development
Current Topics in Medicinal Chemistry Are the Myokines the Mediators of Physical Activity-Induced Health Benefits?
Current Pharmaceutical Design Soy Isoflavones and Cardiovascular Disease Epidemiological, Clinical and -Omics Perspectives
Current Pharmaceutical Biotechnology Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma
Endocrine, Metabolic & Immune Disorders - Drug Targets The Many Antithrombotic Actions of Nitric Oxide
Current Drug Targets Moving Troponin Testing into the 21st Century: Will Greater Sensitivity Be Met with Greater Sensibility?
Cardiovascular & Hematological Disorders-Drug Targets Myricetin Induces Apoptosis in HepG2 Cells Through Akt/p70S6K/Bad Signaling and Mitochondrial Apoptotic Pathway
Anti-Cancer Agents in Medicinal Chemistry Validity of Oxygen-Ozone Therapy as Integrated Medication Form in Chronic Inflammatory Diseases
Cardiovascular & Hematological Disorders-Drug Targets Cardiovascular Complications in Inflammatory Bowel Disease
Current Drug Targets Hypertension - Current Natural Strategies to Lower Blood Pressure
Current Pharmaceutical Design The Double Roles of the Prostaglandin E<sub>2</sub> EP2 Receptor in Intracerebral Hemorrhage
Current Drug Targets Regulatory Roles of the Ubiquitin-Proteasome System in Cardiomyocyte Apoptosis
Current Molecular Medicine Ubiquitin and ubiquitin-like proteins in cardiac disease and protection
Current Drug Targets The Gut and Intestinal Bacteria in Chronic Heart Failure
Current Drug Metabolism Haematopoietic Stem Cell Gene Therapy to Treat Autoimmune Disease
Current Stem Cell Research & Therapy Pharmacological and Non Pharmacological Strategies in the Management of Coronary Artery Disease and Chronic Kidney Disease
Current Cardiology Reviews Atherogenic Versus Non-atherogenic Lipoprotein Profiles in Healthy Individuals. Is There a Need to Change Our Approach to Diagnosing Dyslipidemia?
Current Medicinal Chemistry